SierraMedical Secures Over RMB 100 Million in New Financing Ahead of IPO Filing

Sep 02, 2025 17:03 CST Updated 17:03

Sierra Medical

Innovative Medical Device Developer

News on September 2: Following the securing of hundreds of millions in financing in 2024, Sierra Medical, a leading innovator in ophthalmic medical devices in China, has once again gained favor in the capital market and recently announced the completion of a new round of financing exceeding hundreds of millions. This round of financing was jointly led by Qianji Capital and Shunwei Capital, with continued support from existing shareholders Boxin Capital and Hony Capital.

The funds from this round of financing will be mainly used for the in-depth research and development of the company's first self-developed phacoemulsification and vitrectomy integrated machine product line. At the same time, it will further enrich the company's ophthalmic surgical equipment product portfolio, accelerate the import substitution of high-end domestically produced ophthalmic devices, and expedite the overseas expansion of the company's ophthalmic products.

The successful completion of this round of financing not only reflects the investors' high recognition of Sierra Medical's innovative strength and development prospects, but also injects strong momentum into the company's next stage of development.

In the field of ophthalmic surgical equipment, the market in China has long relied on imported brands. Sierra Medical, with its independent core technology, is gradually breaking this situation.

Ultra-Speed Dual Blade, Chinese Craftsmanship: China-Made NEXVIT® 20K Vitrectomy Probe

As the first domestically produced dual-blade, dual-airflow vitrectomy probe with a cutting speed of up to 20,000 cuts per minute, the NEXVIT® 20K Vitrectomy Probe has garnered significant attention since its launch. The high cutting speed not only enhances surgical efficiency but, more importantly, greatly reduces traction and disturbance to the retina, improving surgical safety. Additionally, the NEXVIT® 20K Vitrectomy Probe features an internationally leading dual-blade, dual-airflow design, complemented by a probe opening that is closer to the retina. This increases suction flow while providing more stable and precise operation, effectively reducing the incidence of intraoperative and postoperative complications. It is safe, reliable, accurate, and efficient, marking a professional path of independent research and production in China with world-class technology.

"One 'Cut' Solution, Precise Protection: Single-Use Ophthalmic Trocar

The ophthalmic trocar is an indispensable and important instrument in vitrectomy surgery. In NEXVIT^®Following the approval and market launch of the 20K vitrectomy cutter, Sierra Medical's independently developed disposable ophthalmic trocar quickly followed suit.

This disposable ophthalmic trocar not only features a sharp blade but also adopts a front-end oblique cutting and cannula edge chamfer design, assisting surgeons in making precise and safe incisions while reducing damage to surrounding ocular tissues, promoting incision closure and postoperative recovery. Supported by the excellent sealing of the cannula and the detachable sealing valve, it helps maintain stable intraocular pressure and meets various surgical requirements.

Today, the world is undergoing a major transformation unseen in a century, with a new round of technological revolution and industrial transformation emerging.Sierra Medical, adhering to the relentless pursuit of advanced technology and keen insight into the industry frontier, has made remarkable contributions by deeply researching and meticulously refining the development and precision manufacturing techniques in the field of ophthalmic minimally invasive vitrectomy surgery. Their efforts have helped break the monopoly of foreign giants, overcome technical barriers, and resolve the "choke point" issue of critical surgical instruments.

In the future, Sierra Medical will continue to actively align with national policy directions, focusing on providing precise, intelligent, and minimally invasive surgical treatment solutions for ophthalmology. It aims to lead the major trend of domestic production of high-end vitrectomy surgical instruments in China, offering innovative and high-quality products and services to ophthalmologists and patients!

About Sierra Medical

Sierra Medical was founded in July 2022. The company's core team has extensive industry experience and possesses complete R&D, production, and commercialization capabilities. Focused on providing precise, intelligent, minimally invasive surgical treatment solutions for ophthalmology, the company is committed to breaking the monopoly of foreign enterprises in the high-end ophthalmic surgical instrument field and resolving the "chokepoint" issue of critical surgical instruments.

▲Source of the article: Yixiu Research Institute

▲Please indicate the above source for reprinting.

Disclaimer: This article is intended solely for the purpose of information transmission and is for reference only. It does not constitute any advice on investment or treatment; please exercise caution. If it involves issues related to the content, copyright, or other aspects of the work, to ensure the rights and interests of both parties, please contact us, and we will handle it immediately. If this article is reprinted by any platform, the platform must take responsibility for the article itself; the Medical Device Innovation Network is not responsible for any secondary dissemination caused by the reprint.

Previous Recommendations

BD, 125.4 Billion Yuan Sale!

Fined $3.2 Billion, Johnson & Johnson Refuses to Comply

$7.2 Billion! Giant Goes Private and Delists

Medical Device Companies in the IPO Race: Who Will Follow in the Footsteps of NorthX Life?